Mikhail Blagosklonny Tenure at Oncotarget
It’s an international, weekly peer-reviewed open medical journal covering research on all aspects of oncology. It is a traditional multidisciplinary journal which is accessed freely. The journal was co-founded in 2010. Impact Journal, a renowned publisher recently published the oncotarget. Mikhail Blagosklonny and Andrei V. Gudkov are the editors- in- chief. Its goal is to make scientific results quickly and extensively available and to increase the effect of research through insightful review. It also gives room for exceptional findings to be shared quickly and connect different areas of biomedical science. Additionally, it has a mission of advancing applications of basic and clinical science to fight infection. The journal helps all researchers to contribute toward the advancement of science under the tenure of the most famous scientists. Oncotarget is a member and subscriber of the standards of the Committee on Publication Ethics. Its target is to employ treatment amenities to improve the management of cancer patients.
About Mikhail Blagoskylonny
Mikhail Blagosklonny is a scientist who specializes in cancer and aging-related issue. On April 15, 2009, he was made a professor of oncology at Roswell Park Cancer Institute in New York. He attended the First Pavlov State Medical University of St. Petersburg where he earned his M.D in Internal Medicine and Ph.D. in Experimental Medicine and Cardiology. Mikhail Blagosklonny served as senior scientist at Ordway Research Institute, New York. Before that, he served as an associate professor of medicine at New York Medical College, Valhalla.
Dr. Blagosklonny is an author of over 170 research articles, book chapters, and reviews. He is the Founding Editor and Editor-in-chief of Cell Cycle. He is also an Associate Editor of Cancer Biology and Therapy, Cancer Research, Cell Death and Differentiation, Autophagy, American Journal of Pathology, International Journal of Cancer, and PLOS ONE. He revealed potential targets for slowing down aging and diseases associated with age.Misha is an accomplished researcher with unique approaches in cancer biology and therapy. His presence will accelerate the development of new anti-cancer tactics and methods of cancer treatment and prevention. The Roswell fraternity was very anxious about his recruitment.